Study: 'Smart drug' Provigil may be habit-forming

Mar 17, 2009 By CARLA K. JOHNSON , AP Medical Writer
An undated photo provided by Frazer, Pa.-based Cephalon, Inc., shows bottles of its presription drug Provigil. A small government study shows that the popular brain-boosting drug may carry a risk of addiction like other popular stimulants. Provigil is approved to treat excessive daytime sleepiness caused by narcolepsy. On the market since 1999, it's the company's flagship product. (AP Photo/Cephalon Inc.)

(AP) -- A so-called "smart drug" popular with young people may carry more of an addiction risk than thought, a small government study suggests. Scans of 10 healthy men showed that the prescription drug Provigil caused changes in the brain's pleasure center, very much like potentially habit-forming classic stimulants. Modafinil, the drug's generic name, is sometimes used as an illegal study aid by college students.

"It would be wonderful if one could take a and be smarter, faster or have more energy," said Dr. Nora Volkow, director of the National Institute on Drug Abuse, who led the study with a Brookhaven National Laboratory scientist. "But that is like fairy tales. We currently have nothing that has those benefits without side effects."

The study, appearing in Wednesday's , may bust the myth that the drug is safe for healthy people, experts said.

is approved to treat excessive daytime sleepiness caused by narcolepsy. On the market since 1999, it's the flagship product of Cephalon Inc. of Frazer, Pa., and its sales approached $1 billion last year. The company is developing a spin-off called Nuvigil.

Modafinil's reputation as a brain enhancer stems from an Air Force study that found it improved the performance of sleep-deprived fighter pilots. College students buy and sell it illegally, as they do Ritalin and Adderall, to stay alert while studying.

Several scientists recently wrote in the journal Nature that healthy people should have the right to boost their brains with pills like Provigil. One author of that commentary, brain scientist Martha Farah of the University of Pennsylvania, said the new study "goes to show that we need a little caution and a little humility when we're messing around with our brain chemistry."

"But even now, after all the years that it has been on the market, we are still learning things about it that are relevant to its safety," Farah said.

The men in the study were 23 to 46 years old. They received either a dummy pill or modafinil. Effects were measured by PET scans, which showed that the drug increased dopamine, the brain's "feel-good" neurotransmitters.

Modafinil once was thought to be safer than conventional stimulants because it was believed that it did not engage the brain's dopamine system, which is linked with addiction. Studies in mice and monkeys suggested otherwise.

The new study is the first human evidence that a typical dose of modafinil affects dopamine in the brain as much as a dose of Ritalin, a controlled substance with clear potential for dependence.

Volkow said modafinil acts slowly when swallowed and is difficult to inject, making it less likely to be abused. Its high price, about $10 per pill compared to Ritalin at $2 per pill, also makes it less attractive to people seeking a high. That may change when generics become available in 2012, Volkow said.

Jeffry Vaught, chief science officer for Cephalon, said the company has seen no evidence the drug is highly abused.

"If abuse is a problem with modafinil, it's minimal at best," Vaught said. "We're not seeing it used at rave scenes."

Prescribing information for the drug warns of severe rashes and other side effects such as headache, nausea and anxiety. Cephalon doesn't support the drug's use as a cognitive enhancer.

"There's no substitute for sleep," Vaught said.

---

On the Net:

JAMA: http://jama.ama-assn.org

©2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Explore further: New sleeping pill poised to hit US markets

add to favorites email to friend print save as pdf

Related Stories

Adult ADHD linked with dopamine levels

Aug 09, 2007

Adults with attention-deficit/hyperactivity disorder have a reduced response to the drug Ritalin, U.S. government scientists have found.

1 sleepless night increases dopamine in the human brain

Aug 19, 2008

Just one night without sleep can increase the amount of the chemical dopamine in the human brain, according to new imaging research in the August 20 issue of The Journal of Neuroscience. Because drugs that increase dopami ...

Recommended for you

New sleeping pill poised to hit US markets

8 hours ago

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Global recommendations on child medicine

9 hours ago

Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...

FDA has safety concerns on Merck insomnia drug

May 20, 2013

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

US adviser on board of firm that sold anthrax drug

May 20, 2013

(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while ...

User comments : 0

More news stories

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...

Encouraging signs for bee biodiversity

Declines in the biodiversity of pollinating insects and wild plants have slowed in recent years, according to a new study. Researchers led by the University of Leeds and the Naturalis Biodiversity Centre in the Netherlands ...

New method for producing clean hydrogen

Duke University engineers have developed a novel method for producing clean hydrogen, which could prove essential to weaning society off of fossil fuels and their environmental implications.